Research Analysts Set Expectations for Ardelyx Q1 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Ardelyx in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a “Neutral” rating and a $5.50 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Citigroup reduced their price objective on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Ardelyx in a report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.42.

Ardelyx Price Performance

Shares of Ardelyx stock opened at $4.59 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.03 and a quick ratio of 3.87. Ardelyx has a fifty-two week low of $3.49 and a fifty-two week high of $10.13. The firm has a fifty day moving average price of $6.01 and a two-hundred day moving average price of $6.29. The company has a market cap of $1.09 billion, a PE ratio of -15.30 and a beta of 0.92.

Institutional Trading of Ardelyx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Ardelyx by 2.8% in the first quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company’s stock valued at $97,761,000 after purchasing an additional 365,809 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Ardelyx by 68.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company’s stock worth $28,572,000 after buying an additional 1,584,597 shares during the last quarter. Millennium Management LLC increased its holdings in Ardelyx by 142.8% during the second quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company’s stock worth $23,735,000 after buying an additional 1,883,995 shares during the last quarter. Redmile Group LLC acquired a new position in Ardelyx during the first quarter worth $16,020,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Ardelyx by 2.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,938,778 shares of the biopharmaceutical company’s stock worth $13,358,000 after buying an additional 40,702 shares during the last quarter. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, insider David P. Rosenbaum sold 49,564 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $6.92, for a total value of $342,982.88. Following the completion of the sale, the insider now owns 301,946 shares in the company, valued at approximately $2,089,466.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Michael Raab sold 32,225 shares of Ardelyx stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $5.86, for a total transaction of $188,838.50. Following the transaction, the chief executive officer now owns 1,227,009 shares of the company’s stock, valued at $7,190,272.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $6.92, for a total transaction of $342,982.88. Following the transaction, the insider now directly owns 301,946 shares in the company, valued at $2,089,466.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 267,983 shares of company stock worth $1,632,802. 5.90% of the stock is currently owned by corporate insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.